Navamedic ASA (OSL:NAVA)

Market Cap	539.58M
Revenue (ttm)	523.56M
Net Income (ttm)	-32.38M
Shares Out	23.98M
EPS (ttm)	-1.85
PE Ratio	n/a
Forward PE	28.39
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,607
Average Volume	265,061
Open	22.10
Previous Close	22.50
Day's Range	22.00 - 22.70
52-Week Range	17.10 - 31.50
Beta	0.31
RSI	55.37
Earnings Date	Oct 28, 2025

About Navamedic ASA

Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Norway, Sweden, Denmark, Finland, the Netherlands, and internationally. The company’s product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic and propioni...

• Industry: Medical Distribution
• Sector: Healthcare
• Founded: 2002
• Employees: 42
• Stock Exchange: Oslo Børs
• Ticker Symbol: NAVA

Financial Performance

In 2024, Navamedic ASA's revenue was 531.44 million, an increase of 3.80% compared to the previous year's 512.00 million. Losses were -5.49 million, -59.92% less than in 2023.